



SLEEP ON DEMAND !!!



ZOLPIGRESS™

Zolpidem Controlled Release Tablet 12.5 mg

La Renon®

ZOLPIGRESS™

Zolpidem Controlled Release Tablet 12.5 mg



Indication:

ZOLPIGRESS is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.

Composition:

Zolpidem tartrate Controlled Release Tablet 12.5 mg.

Mechanism of Action:

Zolpidem tartrate, is a non-benzodiazepine hypnotic of the imidazopyridine class. It interacts with a GABA- benzodiazepine receptor complex and modulation of the GABAA receptor chloride channel macromolecular complex, responsible for sedative, anticonvulsant, anxiolytic, and myorelaxant drug properties.

Zolpidem in vitro condition, binds the (BZ1) receptor preferentially with a high affinity ratio of the alpha1/alpha5 subunits. This selective binding of zolpidem on the (BZ1) receptor is not absolute, but it may explain the relative absence of myorelaxant and anticonvulsant effects in animal studies as well as the preservation of deep sleep (stages 3 and 4) in human studies of zolpidem at hypnotic doses.

Dosage:

Adult - As controlled release tab: 12.5 mg immediately before bedtime.

Administration:

It should be taken on an empty stomach. Do not take with/ or immediately after a meal.

Advantages:

- Zolpidem-12.5mg control release tablet significantly reduces latency to persistent sleep, and significantly increases sleep efficiency, without next-day residual effects. *
- Residual daytime effects are unlikely with recommended doses. **

* *Sleep Medicine* 7 (2006) 397-406

** *SLEEP*, Vol. 31, No. 1, 2008 79-90.

La Renon Healthcare

208-ISCON Elegance | Circle P | Prahlad Nagar Cross Roads
S.G.Highway | Ahmedabad - 380015 | Gujarat | India.
Phone: +91-79-3046-1000 (30 Lines) | Fax: +91-79-3046-1001
E-Mail: info@larenon.com | www.larenon.com

I am _____
Call me on _____
Mail me at _____